Unknown

Dataset Information

0

Antimalarial artemisinin-based combination therapies (ACT) and COVID-19 in Africa: In vitro inhibition of SARS-CoV-2 replication by mefloquine-artesunate.


ABSTRACT: OBJECTIVES:At the end of November 2019, a novel coronavirus responsible for respiratory tract infections (COVID-19) emerged in China. Despite drastic containment measures, this virus, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), spread in Asia and Europe. The pandemic is ongoing with particular hotspot in Southern Europe and America. Many studies predicted a similar epidemic in Africa as that currently seen in Europe and the United States of America. However, reported data do not confirm these predictions. One of the hypotheses that could explain the later emergence and spread of COVID-19 pandemic in African countries is the use of antimalarial drugs to treat malaria, and more particularly artemisinin-based combination therapy (ACT). METHODS:The antiviral activity of fixed concentrations of ACT at concentrations consistent with those observed in human plasma when ACT are administered at oral doses for uncomplicated malaria treatment was evaluated in vitro against clinically isolated SARS-CoV-2 strain (IHUMI-3) in Vero E6 cells. RESULTS:Mefloquine-artesunate exerted the highest antiviral activity with % inhibition of 72.1±18.3% at expected maximum blood concentration (Cmax) for each ACT drug at doses commonly administered in malaria treatment. All the other combinations, artesunate-amodiaquine, artemether-lumefantrine, artesunate-pyronaridine or dihydroartemisinin-piperaquine, showed antiviral inhibition in the same range (27.1 to 34.1%). CONCLUSIONS:Antimalarial drugs for which concentration data in lungs are available, are concentrated from 10 to 160 fold in lungs than in blood. These in vitro results reinforce the hypothesis that antimalarial drugs could be effective as anti-COVID-19 treatment.

SUBMITTER: Gendrot M 

PROVIDER: S-EPMC7426697 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Antimalarial artemisinin-based combination therapies (ACT) and COVID-19 in Africa: In vitro inhibition of SARS-CoV-2 replication by mefloquine-artesunate.

Gendrot Mathieu M   Duflot Isabelle I   Boxberger Manon M   Delandre Océane O   Jardot Priscilla P   Le Bideau Marion M   Andreani Julien J   Fonta Isabelle I   Mosnier Joel J   Rolland Clara C   Hutter Sébastien S   La Scola Bernard B   Pradines Bruno B  

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 20200814


<h4>Objectives</h4>At the end of November 2019, a novel coronavirus responsible for respiratory tract infections (COVID-19) emerged in China. Despite drastic containment measures, this virus, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), spread in Asia and Europe. The pandemic is ongoing with a particular hotspot in Southern Europe and America; many studies predicted a similar epidemic in Africa, as is currently seen in Europe and the United States of America. However, r  ...[more]

Similar Datasets

| S-EPMC9949628 | biostudies-literature
| S-EPMC10387089 | biostudies-literature
| S-EPMC6990477 | biostudies-literature
| S-EPMC4350548 | biostudies-literature
| S-EPMC3472241 | biostudies-literature
| S-EPMC8407563 | biostudies-literature
| S-EPMC8592145 | biostudies-literature
| S-EPMC4856632 | biostudies-literature
| S-EPMC2674465 | biostudies-literature